Produced by JPT Peptide Technologies , a leader in custom peptide synthesis and diabetes reagents
Head-to-Head Efficacy: Tirzepatide Wins 22% vs 15% Weight Loss The most robust head-to-head comparison comes from the SURPASS-2 trial, a 40-week, phase 3 study of 1,879 adults with type 2 diabetes, published in the N Engl J Med
openPR disclaims liability for any content contained in this release
However, Wegovy and Mounjaro are now available and approved for weight loss in the UK
Supplementary information Source data Rights and permissions Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made
Just diet and exercise usually fail